Burning Rock a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test...

According to current guidelines, more than 70% of patients with invasive submucosal colorectal cancer (T1 CRC) undergo a radical operation with lymph node dissection, even though only ~ 10% have lymph node metastasis (LNM). Hence, there is imperative to develop biomarkers ...

Liquid biopsy with minimally invasive emerges as a powerful tool for early screening of breast cancer (BrCa). BrCa derived exosomes which enrich with biological information from their parent cells play essential roles in the evolution and metastasis of BrCa, providing ...

At present, there is no validated marker to identify the subpopulation of patients with advanced gastric cancer (AGC) who might benefit from neoadjuvant...

Predicine, a global molecular insights company, announces the introduction of PredicineCOMPLETE™, the organization’s most comprehensive next-generation liquid biopsy solution that provides genome-wide, genomic and epigenomic insights to capture the mutational landscape and the...

Molecular Stethoscope, a leading precision medicine company pioneering the next-generation cell-free mRNA (cf-mRNA) liquid biopsy, announced publication of the study entitled “Survey of extracellular communication of systemic and organ-specific inflammatory responses through cell free messenger RNA profiling in mice” in eBiomedicine, ...

Liquid biopsy for determining the presence of cancer and the underlying tissue of origin is crucial to overcome the limitations of existing tissue biopsy and imaging-based techniques by capturing critical...

Prostate cancer (PCa) is the 4th most diagnosed cancer and the 8th leading cause of cancer-related death worldwide. Currently, clinical risk stratification models including factors like PSA levels, Gleason...

A study by researchers from Hackensack Meridian John Theurer Cancer Center — part of the Georgetown Lombardi Comprehensive Cancer Center, an NCI...

Despite its high potential, PD-L1 expressed by tumors has not been successfully utilized as a biomarker for estimating treatment responses to immunotherapy. Circulating tumor cells and...